AVTX
Avalo Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Garry A. Neil
IPO Date
2015-10-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Avalo Therapeutics, Inc.
CEO
Garry A. Neil
IPO Date
2015-10-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 679 |
| $16.00 |
| 1 Jun 2026 | Doyle Mittie | Chief Medical Officer | M-Exempt | Disposed | 679 | $8.04 |
| 26 May 2026 | Riley Jennifer | Chief Strategy Officer | A-Award | Acquired | 34,200 | $0.00 |
| 26 May 2026 | Sullivan Christopher Ryan | Chief Financial Officer | A-Award | Acquired | 39,900 | $0.00 |
| 26 May 2026 | VARKI PAUL | Chief Legal Officer | A-Award | Acquired | 24,300 | $0.00 |
| 26 May 2026 | Doyle Mittie | Chief Medical Officer | A-Award | Acquired | 43,500 | $0.00 |
| 26 May 2026 | NEIL GARRY ARTHUR | director, officer: Chief Executive Officer | A-Award | Acquired | 100,200 | $0.00 |
| 19 May 2026 | Doyle Mittie | Chief Medical Officer | M-Exempt | Acquired | 3,000 | $12.65 |
| 19 May 2026 | Doyle Mittie | Chief Medical Officer | S-Sale | Disposed | 3,000 | $18.76 |